Oncomed Pharma (OMED) 13.01 $OMED OncoMed Management to

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 2:21 AM

Oncomed Pharma (OMED) 13.01 $OMED

OncoMed Management to Present at Two Upcoming Investment Conferences
GlobeNewswire - Mon Jun 06, 7:00AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, today announced that company management will participate in the following upcoming investor conferences:
OMED: 13.01 (+0.15)

OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 8:00AM CDT
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab
OMED: 13.01 (+0.15)

OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:04PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 13.01 (+0.15)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 54.16 (+1.03), OMED: 13.01 (+0.15), LGND: 125.86 (+2.13), ANIK: 53.30 (+0.94)

Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 13.01 (+0.15), AZN: 30.11 (unch), BXLT: 46.02 (-0.18), NKTR: 14.92 (+0.62)

Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:33AM CDT
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 71 cents in the first quarter of 2016.
CBM: 54.16 (+1.03), OMED: 13.01 (+0.15), ANIP: 56.51 (-1.61), ILMN: 141.25 (+1.19)

OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, will announce financial results for the quarter ended March 31, 2016 on Thursday, May 5, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review first quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 13.01 (+0.15)

Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 11.71 (+0.36), OMED: 13.01 (+0.15), GSK: 43.38 (+0.04), BMY: 75.28 (+1.20), CELGZ: 1.43 (+0.08)

OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu Apr 21, 3:27PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
OMED: 13.01 (+0.15)

OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
OMED: 13.01 (+0.15)

OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
OMED: 13.01 (+0.15)

OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
GlobeNewswire - Thu Mar 17, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its Phase 1b clinical trial of OncoMed's investigational agent demcizumab (anti-DLL4, OMP-21M18), with Merck's anti-Programmed Cell Death 1 (PD1) therapy pembrolizumab (KEYTRUDA(R)). The combination of these agents may act as a double blockade for cancer-induced immune suppression with potential application to a number of solid tumor cancers.
OMED: 13.01 (+0.15)

OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
GlobeNewswire - Wed Mar 16, 3:30PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology therapeutic candidates in a total of five presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 16-20, 2016 in New Orleans, LA.
OMED: 13.01 (+0.15)

OncoMed Pharmaceuticals to Report Fourth Quarter and Year-End 2015 Financial Results on Thursday, March 10, 2016
GlobeNewswire - Fri Mar 04, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology therapeutics, will announce financial results for the fourth quarter and year ended December 31, 2015 on Thursday, March 10, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review 2015 results, 2016 guidance and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 13.01 (+0.15)

Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 7:45AM CST
OncoMed Pharmaceuticals (OMED) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OMED: 13.01 (+0.15)

OncoMed Tanks on Phase II Pancreatic Cancer Study Update
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 1:30PM CST
OncoMed Pharmaceuticals' (OMED) shares plunged 45% after it provided disappointing update on its pancreatic cancer candidate tarextumab.
OMED: 13.01 (+0.15), BXLT: 46.02 (-0.18), GSK: 43.38 (+0.04), ANIK: 53.30 (+0.94)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OncoMed Pharmaceuticals, Inc.
BusinessWire - Mon Jan 25, 12:36PM CST
Levi & Korsinsky announces it has commenced an investigation of OncoMed Pharmaceuticals, Inc. (NASDAQGS: OMED) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
OMED: 13.01 (+0.15)

Why OncoMed Pharmaceuticals' Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jan 25, 11:53AM CST
What : Shares of OncoMed Pharmaceuticals , a clinical-stage biotech, dropped by more than 46% today on heavy volume after an independent data safety monitoring board reported that the company's midstage pancreatic cancer drug, tarextumab, doesn't...
OMED: 13.01 (+0.15), GSK: 43.38 (+0.04)

Will 2016 Be Celgene Corporation's Best Year Yet?
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 25, 9:38AM CST
Image source: NIH Image Gallery via Flickr. In a year in which the stock market was relatively flat, biotech blue-chip Celgene was a noted outperformer, having gained 5.5% over the 12 months. 2015 was yet another strong year of growth for the...
OMED: 13.01 (+0.15), CELG: 105.03 (+0.62)

OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
GlobeNewswire - Mon Jan 25, 6:30AM CST
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB). The DSMB assessed data from 172 patients treated as of a January 6, 2016 data cutoff date.
OMED: 13.01 (+0.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Patrick Ta Beauty Adds New Leadership to Expand Growth

Angela Simpson and Carolyne Rapp Join the Ranks In the fast-paced world of beauty, where trends shift faster than a day trader’s mood, Patrick Ta Beauty is shaking things up with some heavyweight hires. Angela Simpson steps in as Chief Marketing Officer, and Carolyne Rapp takes the reins as Vice President of Creative. Maybe it’s just me, but when a brand ropes in pros...

Investor Yazan Al Homsi Backs Arcanus Aerial for $500K

Yazan Al Homsi Backs Canadian Innovation Every once in a while, you see a move in the market that feels bigger than the numbers on the page. That's what this $500,000 from Yazan Al Homsi into Arcanus Aerial Systems does. Al Homsi, a UAE-based investor with a solid pedigree, decided to pump half a million bucks into Arcanus just as it's setting down roots in Canadian soil...

Acqualina Resort's Sustainable Commitment Earns Praise

Sustainability at the Heart of Luxury Spotlight's on Acqualina Resort again. The folks there have snagged the 2026 VERIFIED™ Responsible Hospitality badge from Forbes Travel Guide for the third straight year. Means they’re more than just a pretty face down in Miami. This accolade puts them slap bang among the best in sustainable luxury. Forbes doesn’t just hand...

Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

SLM Faces Legal Scrutiny as Losses Mount Amid Pause

SLM's Latest Troubles: Legal and Financial Impact Ah, student loans—not just a headache for borrowers but now for lenders too. SLM Corporation, that name we know all too well in the student debt circus, has hit a snag. They've paused most of their third-party recovery activities. Let's dig in: net charge-offs for SLM in the third quarter shot up to a hefty $90.4...

Better Home & Finance Faces Class Action: What's Next?

Stock Hit and Legal Drama Panic set in when Better Home & Finance Holding Company took a 28.5% nosedive after spilling some less-than-sweet news. Their promise of hitting a billion in monthly loans? Stuck in limbo as borrower trepidation reared its ugly head amidst rising rates. Investors felt the heat, watching shares skydive $12.17, landing them at a bruised $30.52. A...

Infosys Pushes AI Growth with Strong Deal Wins

Riding the AI Wave Who knew Infosys was a lightning rod for AI momentum, eh? With a 29% quarterly surge in AI revenue, the firm's really putting AI strategy at center stage. Considering today's finicky markets, that's not just peanuts. CEO Salil Parekh's swagger is backed by real numbers, seeing AI revenue inch to 10.5% of total haul. This ain't just talk—Infosys is...

Italian Excellence: NYC Celebrates Innovators and Icons

The Fusion of Italian Artistry and Innovation Imagine blending business savvy with a touch of culture and ethics. That's the spirit of the 9th Business Care International Award, which is gearing up to hit New York City's grand stage come November 18-19. This ain't just about pats on the back; it's a recognition of those who push Italian excellence across oceans and into...

NUH Revolutionizes Eye Care with Multidisciplinary Clinics

Looking Back at Four Decades of Eye Care Excellence Sitting in the middle of Singapore, the National University Hospital's Ophthalmology Department has chalked up a solid 40 years serving up top-notch eye care. This ain't just about celebrating another year; it's about shaking things up with fresh approaches to treating tricky eye disorders. They're not resting on any...

Hi3D Unlocks AI 3D Model for Open-Source Innovation

A New Era in 3D Model Accessibility Unless you’ve been hiding under a rock, it’s hard to miss how digital terraforming has shifted gears. With Hi3D V1.0 opening its doors, the playing field's getting a major reshuffle. Or, as they say, the table is being set, and everyone's getting a seat. By letting loose production-validated AI tools, Hi3D is throwing down the...